Key result
Preadmission use of cardioprotective drugs such as aspirin was associated with a lower odds of presenting with STEMI compared to NSTEMI (OR 0.64; 95% CI 0.61-0.67).
Why the study?
Is preadmission use of cardioprotective drugs associated with a lower likelihood of presenting with STEMI versus NSTEMI in patients with first-time myocardial infarction?
Population
72,650 patients aged ≥30 years admitted with a first-time myocardial infarction in Denmark between 2003-2012.
Comparison
Preadmission use of cardioprotective drugs… vs No preadmission use of cardioprotective drugs.
Design
Cohort
Follow-up
1 year
Authors
Loading...
Suggests prior medical therapy may attenuate initial infarct severity; leaves open whether this shift fully explains the.
Cohort (n=72,650)
Yes
Is preadmission use of cardioprotective drugs associated with a lower likelihood of presenting with STEMI versus NSTEMI in patients with first-time myocardial infarction?
Odds Ratio: 0.64 (95% CI 0.61–0.67)
Increased preadmission use of cardioprotective drugs is associated with a lower likelihood of presenting with STEMI compared to NSTEMI, coinciding with a nationwide decline in overall MI incidence.
Smedegaard et al. (2017) conducted a cohort in Myocardial infarction (n=72,650). Preadmission use of cardioprotective drugs (e.g., aspirin) vs. No preadmission use was evaluated on Presentation with STEMI versus NSTEMI (OR 0.64, 95% CI 0.61-0.67). Preadmission use of cardioprotective drugs such as aspirin was associated with a lower odds of presenting with STEMI compared to NSTEMI (OR 0.64; 95% CI 0.61-0.67).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: